Oct 27, 2025 4:30 PM Eastern Daylight Time AngioDynamics to Participate in the UBS Global Healthcare Conference Share LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced, that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, w ...

Shares of NVE Corporation (NVEC) have declined 1.5% since reporting second-quarter fiscal 2026 results on Oct. 22, 2025, compared with a 0.5% drop in the S&P 500 index. Over the past month, the stock has risen 9.7%, outpacing the S&P 500’s 1.5% rally, reflecting investor optimism about the company’s growth prospects despite near-term revenue softness.Earnings & Revenue PerformanceNVE Corp reported total revenues of $6.35 million for the quarter ended Sept. 30, 2025, a 6% decrease from $6.76 million in the p ...

Core Insights - Exact Sciences Corporation (EXAS) is positioned for growth due to the momentum in its Cologuard and Oncotype DX tests, with ongoing investments in innovative cancer diagnostic solutions [1][4][9] - The company has a market capitalization of $10.20 billion and an estimated long-term earnings growth rate of 30.1%, outperforming the industry average of 21% [3] - Exact Sciences aims for 15% compounded revenue growth and over 20% adjusted EBITDA margins, with expected annual savings of more than $150 million by 2026 [5][9] Growth Drivers - Cologuard's growth is supported by rescreens, care gap programs, and improved commercial execution, with a focus on making it the standard of care [4] - Oncotype DX is experiencing strong international uptake, with a significant opportunity for growth as 70% of eligible patients outside the U.S. are not currently tested [4] - The launch of new products, such as Oncodetect and Cologuard Plus, enhances the company's offerings and addresses market needs [6][7][10] Operational Challenges - The company faces macroeconomic pressures, including high-interest rates and limited access to capital markets, which could impact profitability [13] - A competitive landscape in the colorectal cancer screening market poses risks, with competitors having greater resources and capabilities [14] Financial Performance - In the past year, EXAS stock has declined by 13.6%, while the S&P 500 has risen by 18.9% [2] - The Zacks Consensus Estimate for Exact Sciences' 2025 earnings has increased by 13.8% to 33 cents, with revenues projected to reach $3.16 billion, reflecting a 14.4% increase from 2023 [15]

Medical Technology Advancements - Medical technology front may have good news for needle phobic individuals [1] Expert Suggestions - Experts have lots of suggestions for people with needle phobia [1]

Neuralink to Enable Sight for the Completely BlindElon Musk says:“Neuralink starts off as a medical company. Its initial goals are to really help people who are quadriplegic, those who have lost use of their body, and enable them to control their own computer just by thinking.I think we’ve had 8 patients thus far. All 8 loved the device and are using it every day.Next year, we will do the blindsight implant, which will enable people who are completely blind, like they’ve lost both eyes and the optic nerve.” ...

Core Insights - Integer reported Q2 FY2025 GAAP revenue of $476 million, an 11.4% increase from Q2 2024, exceeding analyst estimates by $11.63 million [1] - Adjusted EPS for the quarter was $1.55, reflecting a 19.2% year-over-year growth [1][2] - Management raised profit guidance for FY2025, indicating strong operational performance, particularly in Cardio & Vascular product lines [1] Financial Performance - GAAP revenue for Q2 2025 was $476 million, up from $428 million in Q2 2024, marking an 11.2% increase [2] - Adjusted operating income rose to $81 million, a 14.1% increase from $71 million in the previous year [2] - Adjusted EBITDA increased to $99 million, up 10.2% from $89.8 million year-over-year [2] Business Overview - Integer specializes in contract manufacturing of complex medical device components for large medical technology companies [3] - The company focuses on key product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets [4] Segment Performance - Cardio & Vascular segment saw a 24% year-on-year increase in GAAP sales, reaching $286.9 million, driven by new product launches and acquisitions [6] - Cardiac Rhythm Management & Neuromodulation experienced modest organic growth of 2.3%, aligned with management expectations [6][11] - The "Other Markets" segment reported a 37.9% decline in sales, consistent with the company's strategy to exit the portable medical market [7] Strategic Initiatives - Recent acquisitions, particularly in coating technology, are aimed at enhancing Integer's capabilities and supporting vertical integration [8] - The company plans to continue investing in manufacturing and innovation while pursuing strategic acquisitions [14][15] Guidance and Outlook - Management raised full-year 2025 profit guidance, expecting adjusted operating income between $319 million and $331 million, a potential 16% increase from 2024 [14] - Adjusted EPS guidance for FY2025 is set at $6.25–$6.51, indicating up to 23% growth [14] - Revenue outlook for FY2025 is projected at $1.85 billion–$1.88 billion, reflecting confidence in customer demand and acquisitions [14]

'They took shrapnel from my heart' – the magnets saving lives in Ukraine https://t.co/aSQ6IPPftP ...